Cannabidiol Attenuates Doxorubicin-Related Cardiac Disorders Using Modulation of IL6R Signifying Trail in Adult Male Sprague Dawley

Abstract

<title>Abstract</title> <bold>Background</bold> Chemotherapeutic drugs are widely employed to treat various forms of cancer; nevertheless, they can also have detrimental biological effects, especially on non-tumor cells, and frequently disturb the physiological balance in several organs, the heart foremost among them. The present investigation aimed to ascertain the degree to which CBD oil alleviated the cardiotoxicity resulting from doxorubicin (DOX). <bold>Methods</bold> Fifty male Sprague-Dawley rats weighing 150 ± 25g each were molded into five equal groups. Group 2ndgot an intraperitoneal dosage of DOX (18 mg/kg bwt), while Group1st received distilled water orally. Group 3rd received CBD, Group 5th received 1 ml of CBD (26 mg/kg bwt), and Group 4th received trimetazidine (10 mg/kg bwt). On the eleventh day, both groups (5th and 4th) received a single dosage of doxorubicin (18 mg/kg bwt). Examined were gene expression, immunological tests, biochemical measures, and heart histology. <bold>Results</bold> The injection of CBD (26 mg/kg bwt) not only restored normalcy to the ECG and blood pressure, but it also significantly improved the activity of cardiac enzymes (CK-MB and Troponin I), which is linked to a reduction in triglycerides and cholesterol. Furthermore, there was an improvement in SOD and GSH in the cardiac homogenate and a decrease in oxidative stress, as determined by MDA, and inflammatory markers, such as IL6 and TNF-a. Additionally, there has been a discernible decrease in the expression of the IL6R frequency concentration linked to better heart tissue. Due to its anti-inflammatory and antioxidant properties, CBD may offer protection.